United Therapeutics Boosts Board to 13 Members with Appointment of Esteemed Medical Expert Victor Dzau, M.D.

United Therapeutics Board Expansion Details

United Therapeutics Corporation, a Delaware-based biopharmaceutical firm headquartered in Silver Spring, Maryland, revealed that its Board of Directors has increased from 12 to 13 members. This expansion was approved on July 22, 2026, following a recommendation from the Nominating and Governance Committee. The decision aims to strengthen the board’s expertise as the company advances its development and commercialization of therapies targeting pulmonary and cardiovascular diseases.

Dr. Dzau’s addition enhances the board’s collective medical and scientific knowledge. Initially, he will not serve on any standing committees, allowing him time to integrate and gain familiarity with the company’s operations and strategic priorities.

Profile and Appointment of Victor Dzau, M.D.

Victor Dzau, M.D., joined the Board of Directors effective July 22, 2026. The company disclosed that no arrangements or understandings influenced his selection; the appointment was merit-based and recommended by the Nominating and Governance Committee, which assesses candidates based on qualifications, experience, and strategic alignment.

Since the start of the company’s last fiscal year through the present, there have been no transactions exceeding $120,000 involving Dr. Dzau that would present a direct or indirect material interest, ensuring compliance with Regulation S-K related-party transaction disclosures.

Equity Awards Granted to Dr. Dzau

Upon appointment, Dr. Dzau received equity compensation under United Therapeutics’ 2026 Stock Incentive Plan. The initial grant included 380 restricted stock units and 1,190 stock options, consistent with the standard award for newly appointed non-employee directors. These grants were issued on July 22, 2026, in line with the Director Compensation Program outlined in the company’s definitive proxy statement filed April 29, 2026.

Additionally, he was awarded pro-rata equity compensation for the remainder of the 2026-2027 Board service year, consisting of 350 restricted stock units and 1,110 stock options. Details on vesting schedules, strike prices, and grant-date fair values were not disclosed.

Overview of Director Compensation Program

United Therapeutics operates a standardized non-employee director compensation program governing remuneration for directors who are not employees. The program’s structure and components are detailed in the company’s definitive proxy statement for the 2026 annual shareholder meeting, filed with the SEC on April 29, 2026.

Dr. Dzau will receive further compensation in accordance with this program, potentially including cash retainers, meeting fees, committee service fees, and additional equity awards based on future committee roles. This framework ensures consistent valuation of director service and aligns with industry norms for biopharmaceutical companies of similar scale.

Indemnification Agreement and Governance Safeguards

Effective July 22, 2026, Dr. Dzau entered into United Therapeutics’ standard indemnification agreement for directors and executive officers. This agreement, previously filed as Exhibit 10.1 to the company’s Current Report on October 1, 2021, provides legal protections for directors acting in good faith and in the company’s best interests.

Such indemnification agreements are customary in public companies, offering legal protection and cost coverage to attract and retain qualified directors. The agreement complies with Delaware corporate law and reflects standard biopharmaceutical industry practices.

About United Therapeutics Corporation

United Therapeutics Corporation develops and markets treatments for chronic and life-threatening pulmonary and cardiovascular conditions. Headquartered at 1000 Spring Street, Silver Spring, Maryland, and incorporated in Delaware, the company focuses on innovative therapies for underserved patients. Its common stock trades on the Nasdaq Global Select Market under the ticker UTHR.

As a publicly traded entity, United Therapeutics maintains strong governance and compliance mechanisms to safeguard shareholder interests and ensure accountability. The recent board expansion highlights its dedication to a diverse, experienced, and engaged leadership team capable of overseeing complex strategic initiatives.

Regulatory Filings and Disclosure Compliance

The company filed a press release on Dr. Dzau’s appointment as Exhibit 99.1 to its Current Report on Form 8-K dated July 23, 2026. The information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and thus not subject to Section 18 liabilities under the Securities Exchange Act of 1934. This distinction is important for regulatory and legal purposes.

The press release and related disclosures are not incorporated by reference into any Securities Act of 1933 or Securities Exchange Act of 1934 filings unless explicitly stated, limiting liability exposure and ensuring compliance with federal securities laws.

Significance for Investors and Governance Analysts

The addition of Dr. Dzau and the board’s expansion to 13 members mark important governance developments that investors and market observers may track for their impact on United Therapeutics’ strategic direction and decision-making. Changes in board composition can influence corporate strategy, capital allocation, and risk oversight.

Stakeholders may watch for future announcements regarding Dr. Dzau’s committee assignments or strategic initiatives, as board expansions often coincide with business transitions, new therapeutic area entries, or shifts in competitive positioning. Understanding these changes offers insight into management’s confidence and outlook within the biopharmaceutical sector.